Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Receive conference highlights, journal articles, and online medical education activities straight to your inbox.

Never Miss an Update

Foreword – touchREVIEWS in RMD, Volume 4, Issue 1, 2025

From advances in targeted therapies to the integration of AI and steps towards precision medicine, 2024 brought many exciting developments in the field. With 2025 now unfolding, many of these are likely to continue gaining momentum and potentially redefine patient care. In this latest edition of touchREVIEWS in RMD, we’re excited to present a collection […]

Axial Spondyloarthritis

Marina Magrey, ACR 2020 – Prognosis and Unmet Need in Nr-axSpA

Published Online: Nov 30th 2020

TouchIMMUNOLOGY was delighted to speak with Marina Magrey (Case Western Reserve University School of Medicine/ MetroHeath Medical Center, Cleveland, OH, USA) about non-radiographic axial spondyloarthritis (nr-axSpA), its prognosis and the unmet needs in its treatment.

Disclosures: Marina Magrey has served as a consultant for Novartis, Eli Lilly, Pfizer, AbbVie, UCB and Janssen. She has also performed research for Amgen and is currently doing research with AbbVie and UCB Pharmacy.

Support: Interview and filming supported by Touch Medical Media Ltd.

Filmed in coverage of virtual ACR Convergence 2020.

Bimekizumab on structural damage in r-axial SpA & remote monitoring vs face-to-face

In our late-breaking abstract coverage, we spoke with Prof. Denis Poddubnyy from Charité-Universitätsmedizin Berlin to discuss key data from EULAR 2024 on axial spondyloarthritis (axSpA). We first explored the open-label extension results of the phase 3 BE MOBILE 2 study (NCT04436640), which assessed bimekizumab's impact on 2-year radiographic progression in the spine of patients with radiographic axSpA. Hypothesized to offer superior inhibition of bone formation due to its dual action on IL-17A and IL-17B, bimekizumab's findings were compared with other treatments like ixekizumab, upadacitinib, secukinumab, and certolizumab pegol, highlighting implications for clinical practice. Additionally, we examined a recent study by Berg et al., which compared remote monitoring and patient-triggered monitoring to traditional face-to-face consultations. The discussion focuses on how these findings could influence daily practice, patient outcomes, and healthcare resource management.

Related Videos in Axial Spondyloarthritis

Developed by Touch

Efficacy of secukinumab as first-line bDMARD vs standard-of-care

International guidelines emphasize achieving remission or low disease activity in axial spondyloarthritis (axSpA) through a treat-to-target approach. Despite this, choosing the optimal first or second-line treatment remains challenging due to limited comparative data. The Treat-to-Target in Axial Spondyloarthritis (AScalate) trial (NCT03906136) aimed to assess the efficacy of the IL-17 inhibitor secukinumab as a first-line treatment versus standard care. At EULAR 2024, Prof. Denis Poddubnyy presented the study results, offering insights into the trial’s rationale, design, and key findings. This interview explores these aspects and discusses their implications for clinical practice.

Developed by Touch

Axial spondyloarthritis treatment paradigm and unmet needs: Fabian Proft, EULAR 2023

Axial spondyloarthritis is a chronic, inflammatory rheumatic disease that affects the axial skeleton, causing severe pain, stiffness and fatigue. touchIMMUNOLOGY were delighted to speak with Dr Fabian Proft (Charité Universitätsmedizin Berlin, Germany) about the treatment paradigm and unmet needs ...

Developed by Touch

BE MOBILE 1 and BE MOBILE 2: phase 3 studies of bimekizumab in axial spondyloarthritis: Fabian Proft, EULAR 2023

BE MOBILE 1 and BE MOBILE 2 are double-blind, phase 3 trials designed to evaluate efficacy and safety of bimekizumab, a novel dual interleukin (IL)-17A and IL-17F inhibitor, across the axial spondyloarthritis spectrum. touchIMMUNOLOGY were delighted to speak with Dr ...

Developed by Touch

Xenofon Baraliakos, ACR 2022: Bimekizumab in the treatment of active non-radiographic axial spondyloarthritis and ankylosing spondylitis - 52 week findings from BE MOBILE 1 and 2

Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits both IL-17F and IL‑17A, was recently investigated in the phase 3 BE MOBILE 1 (NCT03928704) and BE MOBILE 2 (NCT03928743) clinical trials for active non-radiographic axial spondyloarthritis and ankylosing spondylitis, respectively. touchIMMUNOLOGY were ...

Developed by Touch

Sofia Ramiro, ACR 2022: Ixekizumab for radiographic axial spondyloarthritis - findings from the COAST-V trial

The COAST-V trial (NCT02696785) investigated the efficacy and safety of ixekizumab in patients with radiographic axial spondyloarthritis who were biological disease-modifying anti-rheumatic drug naïve. It was a pleasure to talk with Dr. Sofia Ramiro (Leiden University Medical Center, Leiden, ...

Developed by Touch

Xenofon Baraliakos, EULAR 2022: Bimekizumab in Patients with Active Non-Radiographic Axial Spondyloarthritis - BE MOBILE 1

BE MOBILE 1 (ClinicalTrials.gov Identifier: NCT03928704) is a a phase 3 study investigating bimekizumab in the treatment of active non-radiographic axial spondyloarthritis. touchIMMUNOLOGY were delighted to speak with Prof. Xenofon Baraliakos (Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany) around the aims of ...

Denis Poddubnyy, ACR 2021: Secukinumab and HLA Subtypes in AxSpA

Prof. Denis Poddubny (Charité-Universitätsmedizin Berlin, Berlin, Germany) kindly took the time to speak with touchIMMUNOLOGY about the post-hoc analysis from the phase 3b SKIPPAIN trial (NCT03136861) aimed at exploring the potential association of HLA-B27 subtypes on the effect ...

Inna Gaydukova, EULAR 2021: Netakimab in Patients with Ankylosing Spondylitis with or without Sacroiliitis

It was a pleasure to meet with Professor Inna Gaydukova (North-Western State Medical University, St. Petersburg, Russia) to talk around the changes in ankylosing spondylitis activity in patients with and without sacroiliitis on netakimab treatment. 'NETAKIMAB REDUCES ANKYLOSING SPONDYLITIS ACTIVITY ...

Peter Taylor, EULAR 2021: Highlights from the Congress

We had the pleasure to meet with our Editor-in-Chief, Professor Peter C Taylor (University of Oxford, Oxford, UK) who gave us some of the key highlights from this year's European Congress of Rheumatology meeting, 2-5 June 2021. Questions What were the ...

Anna Moltó, ACR 2020: TICOSPA Trial in Axial Spondyloarthritis

It was a delight to discuss with Anna Moltó (Hospital Cochin, Paris, France) the results of the TICOSPA trial (NCT03043846) which was designed to evaluate the benefit of treat-to-target in patients with axial spondyloarthritis. The abstract entitled ‘Cluster-randomized Pragmatic Clinical ...

Marina Magrey, ACR 2020 - Ixekizumab Response in Nr-axSpA Based on HLA-B27 and Disease Duration: The COAST-X Study

It was a pleasure to speak with Marina Magrey (Case Western Reserve University School of Medicine/ MetroHeath Medical Center, Cleveland, OH, USA) about the recent post-hoc analysis from the COAST X study (NCT02757352). The analysis was designed to evaluate the ...

Walter Maksymowych, ACR 2020 - Predictors of Response in Nr‑axSpA Treated with Certolizumab Pegol: The C-axSpAnd Study

Walter Maksymowych (University of Alberta, Alberta, Canada) talks to touchIMMUNOLOGY about the results of the C-axSpAnd Study (NCT02552212). This 52-week placebo-controlled study aimed to identify demographic or baseline characteristics of patients with nr-axSpA that could be predictive of achieving a ...

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.

Error:

Forgot Password?

Or log in with

By proceeding, you agree to our terms & conditions.

For information about how we
use your data, see our privacy policy.

Register now for FREE Access

Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.

Already have an Account?

Sign up with an Email

Or use a Social Account.

Error:

By clicking sign up you agree to the website
terms & conditions and privacy policy.

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Conference Coverage

Learning Activities

Journals

Foreword – touchREVIEWS in RMD, Volume 4, Issue 1, 2025

Conference Coverage

Learning Activities

Journals

Foreword – touchREVIEWS in RMD, Volume 4, Issue 1, 2025

Marina Magrey, ACR 2020 – Prognosis and Unmet Need in Nr-axSpA

Bimekizumab on structural damage in r-axial SpA & remote monitoring vs face-to-face

Efficacy of secukinumab as first-line bDMARD vs standard-of-care

Axial spondyloarthritis treatment paradigm and unmet needs: Fabian Proft, EULAR 2023

BE MOBILE 1 and BE MOBILE 2: phase 3 studies of bimekizumab in axial spondyloarthritis: Fabian Proft, EULAR 2023

Xenofon Baraliakos, ACR 2022: Bimekizumab in the treatment of active non-radiographic axial spondyloarthritis and ankylosing spondylitis - 52 week findings from BE MOBILE 1 and 2

Sofia Ramiro, ACR 2022: Ixekizumab for radiographic axial spondyloarthritis - findings from the COAST-V trial

Xenofon Baraliakos, EULAR 2022: Bimekizumab in Patients with Active Non-Radiographic Axial Spondyloarthritis - BE MOBILE 1

Denis Poddubnyy, ACR 2021: Secukinumab and HLA Subtypes in AxSpA

Inna Gaydukova, EULAR 2021: Netakimab in Patients with Ankylosing Spondylitis with or without Sacroiliitis

Peter Taylor, EULAR 2021: Highlights from the Congress

Anna Moltó, ACR 2020: TICOSPA Trial in Axial Spondyloarthritis

Marina Magrey, ACR 2020 - Ixekizumab Response in Nr-axSpA Based on HLA-B27 and Disease Duration: The COAST-X Study

Walter Maksymowych, ACR 2020 - Predictors of Response in Nr‑axSpA Treated with Certolizumab Pegol: The C-axSpAnd Study

Latest articles videos and clinical updates - straight to your inbox

Connect With Us

Useful Links

In Partnership With

Specialities

Sign Up for Free Access to the Latest Clinical Updates in Your Specialty!

Conference Coverage

Learning Activities

Journals

Trending Topic

Connect With Us:

Marina Magrey, ACR 2020 – Prognosis and Unmet Need in Nr-axSpA

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Register now for FREE Access

Sign up with an Email

This Functionality is forMembers Only

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

This Functionality is for
Members Only